Growing evidence points to a deregulated response to Epstein-Barr virus (EBV) 
Summary
Growing evidence points to a deregulated response to Epstein-Barr virus (EBV) in the central nervous system of patients with multiple sclerosis (MS) as a possible cause of disease. We have investigated the response of a subpopulation of effector CD8 + T cells to EBV in 36 healthy donors and in 35 patients with MS in active and inactive disease. We have measured the expression of markers of degranulation, the release of cytokines, cytotoxicity and the regulation of effector functions by inhibitory receptors, such as programmed death 1 (PD-1) and human inhibitor receptor immunoglobulin-like transcript 2 (ILT2). We demonstrate that polyfunctional cytotoxic CD8 + CD57 + T cells are able to kill EBV-infected cells in healthy donors. In contrast, an anergic exhaustion-like phenotype of CD8 + CD57 + T cells with high expression of PD-1 was observed in inactive patients with MS compared with active patients with MS or healthy donors. Detection of CD8 + CD57 + T cells in meningeal inflammatory
infiltrates from post-mortem MS tissue confirmed the association of this cell phenotype with the disease pathological process. The overall results suggest that ineffective immune control of EBV in patietns with MS during remission may be one factor preceding and enabling the reactivation
Introduction
Multiple sclerosis (MS) is an inflammatory and possibly autoimmune disease of the central nervous system (CNS) defined by areas of chronic inflammation with demyelination, axonal damage and loss of neurons. 1 The cause for the autoreactivity of the immune system against the CNS in patients with MS has been the subject of intensive research. Evidence that individuals who contracted mononucleosis during adolescence show more susceptibility to develop the disease 2, 3 suggests that infection by Epstein-Barr virus (EBV) could be a trigger for an autoimmune response in MS. In support of this notion, peripheral blood from patients with MS shows an increased T-cell response to EBV antigens, especially to EBV nuclear antigen 1 (EBNA1). [4] [5] [6] EBV was detected in 
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meningeal tertiary lymphoid structures and in white matter lesions in post-mortem CNS tissue from patients with MS. [7] [8] [9] In addition, in inflamed cerebral meninges of post-mortem MS brain tissue, infiltrates of effector and cytotoxic CD8 + T cells and innate immune responses characterized by interferon-a production have been detected in proximity to EBV-infected plasma cells. 8, 10 Therefore, the observed increase of CD8 + T cells specific for EBV lytic antigens in the peripheral blood and cerebrospinal fluid (CSF) of patients with MS during relapses suggests a close association between replication of EBV in the CNS and inflammatory disease activity. [11] [12] [13] Also, the evidence for active replication of EBV in patients with MS indicates that the virus has the capacity to escape immune control by cytotoxic lymphocytes. 11 However, the results from other studies examining the involvement of EBV infection in the MS pathological process diverged. EBV was undetectable in a heterogeneous B-cell infiltrate in white matter lesions (both adult and paediatric MS) and in B-cell infiltration within the meninges and parenchymal B-cell aggregates in MS brain tissue. 14 In another study, EBV-specific transcripts were not detected in active and chronic active MS plaques rich in perivascular B-lymphocyte cuffs or in single B lymphocytes and in plasma cells isolated from MS patients' CSF. 15 The 22, 23 and after bone marrow transplantation for treatment of aggressive forms of the disease. 24 Although CD8 + CD57 + T cells were observed increasing in the blood of patients with MS after diseasemodified drugs and therapy leading to the reconstitution of the immune system, their role in the disease remains unknown.
An anergic exhaustion-like phenotype regulated through the programmed death 1/programmed death ligand 1 and 2 (PD-1/PDL-1 and PDL-2) pathway has been described recently in virus-specific CD8  + T cells in  chronic human immunodeficiency virus,  25,26 hepatitis C  virus,  27,28 hepatitis B virus  28,29 and human T-lymphotropic virus infections;  30 effector CD8  + T cells can  become unresponsive to viral antigens and consequently  fail to eliminate the viral load. 31,32 PD-1 and human inhibitor receptor immunoglobulin-like transcript 2 (ILT2/CD85j) regulate activation, proliferation and cytokine release from CD8 + T cells and natural killer cells, respectively. [33] [34] [35] [36] In this study, we have investigated the role of PD-1 and ILT2/CD85j in regulating EBV-specific CD8 + CD57 + T cells and the association of PD-1 and ILT2 expression with disease activity in MS. To address these issues, we have investigated the expression of the degranulation marker CD107a, the release of pro-inflammatory cytokines and cytotoxic granules by CD8 + CD57 + T cells, and their ability to kill EBV-infected cells. We then correlated the activity of CD8 + CD57 + T cells to the expression of the inhibitory receptors PD-1 and ILT2 in healthy donors and in patients with MS in stable versus active phases of the disease.
We demonstrate that CD8 + CD57 + T cells are polyfunctional effector cells with a strong ability to recognize and to kill EBV-infected B cells. Moreover, we find that the expression of the PD-1 receptor modulates the activation and cytokine release by CD8 + CD57 + T cells. We observe significant up-regulation of the expression of PD-1, indicating an exhausted phenotype in CD8 + CD57 + T cells in patients with MS in the remitting phase of the disease compared with healthy donors, supporting the hypothesis of impaired responses to EBV in patients with MS. Interestingly, we have detected infiltrates of CD8 + CD57 + T cells in the meninges of post-mortem brain tissue of patients with MS with rapidly progressive disease suggesting the likely involvement of these cells in the disease process.
Materials and methods

Patients
Blood samples were collected from 36 healthy donors and 35 patients with a diagnosis of relapsing-remitting MS (RR-MS). The project received ethics committee approval from the National Research Ethics Service (reference number 05/MRE12/8) and patients gave their written informed consent before taking part in the study. Patients with MS were categorized as stable if they were in clinical remission for at least 3 months and did not present gadolinium-enhancing lesions on brain magnetic resonance imaging, or active if they had presented clinical relapses in the previous 3 months before the enrolment and the blood samples were obtained before any corticosteroid therapy. At the time of blood sampling, all ª 2017 John Wiley & Sons Ltd, Immunology, 152, 660-676 recruited patients were either untreated or during a 2-month washout between therapies. The patients' demographic and basic clinical characteristics and their prior treatments are shown in Table 1 .
Cells and flow cytometry
Peripheral blood mononuclear cells (PBMC) were isolated from blood samples as described. 37 The cells were counted by using trypan blue solution (Sigma-Aldrich Co Ltd, Irvine, UK) and suspended at 1 9 10 6 cells/ml in RPMI-1640 complete medium.
Fresh PBMC were stimulated with PMA and ionomycin (Iono) (Sigma-Aldrich), 500 nM and 50 nM, respectively, for 5 hr at 37°with 5% CO 2 . Brefeldin A (Sigma-Aldrich) was added for the last 4 hr at a concentration of 5 lM. Cells were then collected and prepared for surface and intracellular staining as described below.
Surface staining: PBMCs were stained with the following surface antibodies: phycoerythrin (PE) -conjugated anti-CD3 (BD Biosciences, Oxford, UK), allophycocyanin (APC) -conjugated anti-CD3 (BD Biosciences), PE-Cy7-conjugated anti-CD8 (eBioscience, San Diego, CA), FITCconjugated anti-CD57 FITC (Life Technologies Ltd, Paisley, UK), APC-conjugated anti-PD-1 and APC-conjugated anti-ILT2 APC (eBioscience) on ice for 15 min; cells were then washed in PBS and sample acquisition and analysis were performed on a FACScalibur flow cytometer (BD UK Limited, Berkshire, UK).
Intracellular staining: after surface staining, the cells were washed in PBS and the pellet was suspended in fixation buffer (BD Biosciences) for 20 min at room temperature in the dark. Then, the cells were washed in permeabilization buffer 1 9 (BD Biosciences) and stained with the following intracellular antibodies: APC-conjugated anti-Granzyme B, anti-Perforin and anti-IFN-c; PE-Cy7-conjugated anti-macrophage inflammatory protein 1b (MIP-1b; eBioscience) and PE-conjugated anti-interleukin 2 (BD Biosciences).
EBV-containing supernatant: marmoset cell line B95-8 cells were suspended in complete medium at a concentration of 1 9 10 6 and left for 3 days in a humidified 37°, 5% CO 2 incubator. Then, the supernatant was centrifuged at 270 g, at 4°to separate the EBV-containing culture supernatant from the cells and filtered through a 0Á45-lm filter.
Autologous EBV-infected B-lymphoblastoid cell lines (B-LCL): 2 9 10 6 PBMC were centrifuged and the pellet was infected for 2 hr with 2Á5 ml of EBV-containing culture supernatant obtained as described above and left in the incubator. Then, 5 ml of RPMI complete medium containing 1 lg/ml cyclosporine A was added and the cells were left in the incubator until microscopic clumps were evident and the culture medium became acidic. The cells were split weekly with the addition of RPMI complete medium.
Degranulation assay
PBMC were seeded at 1 9 10 6 cells/well in polystyrene 96-well V-bottomed plates coated with purified anti-CD3 10 lg/ml (OKT3, eBioscience). 16 The assay was performed as described previously. 38 In blocking experiments, PBMC were stained with purified anti-PD-1 antibody (eBioscience) on ice for 15 min. Then, the cells were washed with PBS and stained with purified anti-IgG antibody (eBioscience) on ice for 15 min, washed again and stimulated in 96-well V-bottomed plates as described above. After 4 hr, the cells were collected, washed with PBS and stained for surface and intracellular markers and acquired as described above.
Evaluation of cytotoxicity
P815 murine cell lines and autologous B-LCL were stained with 5 lM carboxyfluorescein succinimidyl ester (CFSE) as described previously. 39 B-LCL were also stained with anti-CD19 APC to separate the lymphoblastoid cell line from lymphocytes. Sorted CD8 + CD57 +/-T cells (CD8 + CD57 + T kit; Miltenyi Biotec Ltd, Surrey, UK) were seeded with a constant number of target cells (50 000) at different effector to target (E : T) ratios in anti-CD3 (10 lg/ml, Thermo Fisher Scientific) pre-coated 96-well V-bottomed plates in a total volume of 200 µl and left in the incubator for 4 hr as described elsewhere. 16, 40, 41 In parallel, target cells were incubated alone to measure spontaneous apoptosis and used for comparative analysis. Then, 1 lM of 7-aminoactinomycin B (7-AAD; Sigma-Aldrich) was added for 15 min on ice in the dark and the sample was then acquired on the flow cytometer. 41 For each E : T ratio, 20 000 target cells were acquired. Dead target cells were detected as double-positive CFSE-7-AAD cells. The percentage of cytotoxic activity (delta cells) was calculated by using the following equation:
Co-culture of PBMC and autologous B-LCL
PBMC were seeded at 1 9 10 6 cells/ml per well or in transwells with or without autologous B-LCL for 5 days. Then, the cells were collected and seeded on anti-CD3 coated V-bottomed plates for 4 hr in the presence of PE-conjugated anti-CD107a as described previously. 38 Then the cells were collected and stained for surface markers and intracellular cytokines as reported above.
Detection of apoptotic cells
PBMC were seeded and stimulated with anti-CD3 at concentrations of 1 and 5 µg/ml for 4 and 24 hr. Then the cells were collected, stained for surface receptors, Annexin V (1 lg/ml, eBioscience) and 7-AAD (1 lg/ml) and acquired on the flow cytometer.
Detection of CD8 + CD57 + T cells in post-mortem MS tissue
Brains were obtained at autopsy from the UK MS Society Tissue Bank at Imperial College, under ethical approval by the National Research Ethics Committee (08/MRE09/ 31). Post-mortem tissue material from individuals with RR-MS was not available for our study. To make our brain tissue analysis of the expression of CD57 more closely representative of the inflammatory pathology expected in RR-MS, we selected from the available secondary progressive multiple sclerosis (SP-MS) cases those who presented on-going active demyelination characterized by the presence of high levels of meningeal and perivenular inflammatory infiltrates. The presence of CD3 + and CD8 + CD57 + T cells, both in the perivascular spaces and in the meninges, was evaluated by immunofluorescence and immunohistochemistry on 4% paraformaldehyde fixed frozen section or formaldehydefixed paraffin sections, respectively, from 10 post-mortem SP-MS patients with rapidly progressive disease (see Supplementary material, Table S1 ). For each of the examined SP-MS cases, five perivascular infiltrates and five meningeal infiltrates, randomly selected among different brain regions, were examined and the percentage of CD3 + CD57 + cells out of the total CD3 + T-cell number was evaluated for each infiltrate. De-waxed 5-lm-thick paraffin sections were microwave-processed in citrate buffer (pH 6) and immunostained by using mouse anti-CD3 antibody (Clone PS1; Immunotech, Marseille, France), mouse anti-CD8 (clone 4B11; Invitrogen, Rockford, IL) or mouse anti-PD-1 (eBioscience), followed by signal detection using the avidin-biotin-peroxidase method, haematoxylin counterstain and mounting with Canadian Balsam, as previously described. 8, 42 Images were acquired and analysed with an Axiophot microscope (Carl Zeiss, Jena, Germany) equipped with a digital camera (Axiocam HRC). For double immunofluorescence, rabbit anti-CD57 antibody (Abcam, Cambridge, MA) was used with mouse anti-CD3 or anti-CD8 or PD-1 antibodies followed by ments shown as mean AE SEM, Mann-Whitney non-parametric t-test *P < 0Á05, **P < 0Á01, ***P < 0Á001, ****P < 0Á0001. 
Statistical analysis
The statistical analyses were performed using GRAPHPAD PRISM software (version 6; GraphPad Software, La Jolla, CA) using the appropriate following tests as specified in the figure legends: Mann-Whitney non-parametric t-test, Wilcoxon t-test, two-way analysis of variance Sidak's multiple comparison, Welch's non-parametric t-test, oneway analysis of variance Turkey's multiple comparisons test and Pearson correlation coefficient. Statistical significance was retained for P-values < 0Á05.
Results
Pro-inflammatory and cytotoxic profile of CD8 + CD57 + T cells CD57 +/-CD8 + T cells were investigated for the release of a panel of pro-inflammatory cytokines and cytotoxic granules as shown in Fig. 1(a) Considering that PD-1 and ILT2/CD85j inhibit T-cell activation, cytokine production and natural killer IFN-c release, 36, 43 we have investigated the role of these two inhibitory receptors in the regulation of effector CD8 + CD57 + T-cell function. As shown in Fig. 3(a) , the content of the granules released by CD8 + CD57 + T cells upon TCR triggering was identified by the co-expression of the lysosomal marker CD107a with granzyme B, perforin and IFN-c. We also examined the correlation between granule content with PD-1 (Fig. 3b) (Fig. S2) . There was an inverse correlation between CD107a and PD-1 expression on CD8 + CD57 + T cells (**P < 0Á01, *P < 0Á05, respectively). Hence, the increased expression of PD-1 on CD8 + CD57 + T cells correlates with the progressive loss of the ability to release IFN-c, perforin and granzyme B (*P < 0Á05, **P < 0Á01). No significant correlation with ILT2 was observed.
CD8
+ CD57 + T cells increase CD107a expression and cytotoxicity in response to autologous EBV-infected lymphoblastoid B cell lines (B-LCL)
We performed co-culture experiments with autologous EBV B-LCL and investigated the reactivity of CD8 + CD57 + T cells to EBV compared with the CD8 + CD57 -counterpart by evaluating degranulation and release of cytokines. CD8 + CD57 + T cells showed a significant increase in the expression of CD107a (*P < 0Á05), in granzyme B degranulation and in IFN-c release (*P < 0Á05) when PBMC were incubated with autologous EBV B-LCL or in transwells compared with PBMC alone (Fig. 4) . No significant activation was observed on CD8 + CD57 -T cells. These results demonstrate that CD57 is a marker expressed by EBV-specific effector and cytotoxic CD8 + T cells.
PD-1 expression on CD8 + CD57 + T cells is associated with reduced cytotoxicity to the p815 murine cell line and autologous EBV B-LCL
+ CD57 + T cells from different donors showed varying degrees of cytotoxicity to p815 and autologous B-LCL. We observed an inverse correlation between cell death and PD-1 expression at E : T cell ratios of 0Á5 : 1 and 1 : 1 in p815 cell line experiments and at a ratio of 30 : 1 in EBV-infected B-LCL experiments, respectively (*P < 0Á05) (Fig. 5c,d) . The results suggest that PD-1 expression is negatively associated with cytotoxicity of CD57 + CD8 + T cells. Furthermore, the expression by autologous EBV B-LCL of a known ligand for PD-1, PDL-1, was investigated. PDL-1 was indeed expressed by EBV-infected B-LCL (see Supplementary material, Fig. S1c) . Also, the p815 murine cell line showed expression of PDL-1 and PDL-2, as reported. 44 Blockade of PD-1 receptor restores cytotoxicity to target cells and cytokine release in CD8 + CD57 + T cells
Having detected a correlation between PD-1 expression and the reduced cytotoxicity against autologous B-LCL, in subsequent experiments we hypothesized that the degranulation of cytotoxic granules, the cytokine release by CD8 + CD57 + T cells and cytotoxicity to autologous EBVinfected B-LCL could be enhanced following blocking of PD-1. Indeed, blocking PD-1 significantly increased the degranulation of granzyme B and perforin and IFN-c release compared with untreated controls (Fig. 6a ,b, *P < 0Á05).
To confirm the functional effect of PD-1 blocking, sorted CD8 + CD57 + T cells were treated with anti-PD-1 and cytotoxicity was measured as the percentage of cell death at increasing E : T cell ratios (Fig. 6c) . Blocking of PD-1 significantly increased the cytotoxicity to EBV B-LCL at the higher E : T cell ratios (10 : 1 *P < 0Á05; 30 : 1 **P < 0Á01) compared with cytotoxicity without PD-1 blocking.
PD-1 is differentially expressed in healthy donors and patients with MS
We investigated the expression of PD-1 by CD8 + CD57 + T cells in patients with MS in both the active and stable phase of the disease, not undergoing treatment. Significantly increased expression of PD-1 was observed on CD8 + CD57 + T cells in patients with stable MS compared with healthy controls (**P < 0Á01, Fig. 7a ). The expression of PD-1 in patients with MS with active disease was not significantly different from that of healthy controls.
We then examined the cytokine release and cytotoxic degranulation by CD8 + CD57 + T cells upon TCR activation in the same set of patients with MS. Interestingly, CD8 + CD57 + T cells showed lower release of IFN-c and granzyme B in patients with stable MS compared with healthy donors and patients with relapsing disease (Fig. 7b , **P < 0Á01). The difference in cytokine release and in degranulation between patients with relapsing MS and active disease was not statistically significant. No significant differences in perforin release were observed among the healthy donors, and in patients with stable MS and active MS.
The fraction of apoptotic cells undergoing activationinduced cell death was also investigated at different timepoints, namely 4 and 24 hr (Fig. 7c,d , respectively) from TCR activation (1 and 5 lg of anti-CD3). We observed significant induction of apoptosis in CD8 + CD57 + T cells from healthy controls at 4 hr. No significant apoptosis was observed in patients with MS patients at either 4 or 24 hr. Our results confirm that CD8 + CD57 + T cells from patients with MS show more resistance to activationinduced cell death than those from healthy donors (*P < 0Á05, **P < 0Á01, ***P < 0Á001). (Fig. 8a-c) , both perivascular and meningeal, corresponded approximately to the number of CD8 + CD57 + cells in the same infiltrates ( Fig. 8d-f ; see Supplementary material, Table S1 ). However, occasional CD8 -CD57 + cells were also observed in the examined infiltrates (green arrow in Fig. 8f ). The percentage of CD57 + cells within the CD3 + T-cell population in the infiltrates was 10Á8% (range 6Á6-14%) in the perivascular infiltrates, and 11Á8% (range 8-15Á4%) in the meninges. PD-1 expression was also assessed using immunohistochemistry on serial sections from the same post-mortem MS cases: several scattered PD-1 + cells were detected, in particular in meningeal infiltrates (Fig. 8g,h ). Double immunofluorescence demonstrated that a substantial proportion (20- + CD57 + cells and age at disease progression (r = 0Á4648, P = 0Á0299); and age at death (r = 0Á7185; P = 0Á0020) indicating an association of the relative frequency of CD57 + T cells with the rapidity of disease progression (Fig. 8k,j) .
Discussion
In this study, we sought to elucidate the mechanism of effector responses by CD8 + CD57 + T cells against EBV in patients with RR-MS and to correlate the responses to disease activity status. We demonstrate that CD8 + CD57 + T cells are a population of effector cytotoxic cells with strong ability to kill EBV-infected cells. A potential role for EBV in MS is supported by strong epidemiological evidence [45] [46] [47] but the presence of EBV infection in MS tissue remains controversial. 9, 15, 48 A characterization of the cytotoxic CD8 + T-cell response against EBV, its regulation and its relationship to MS disease activity may contribute to a better understanding of the immunopathological processes in MS and help to develop new therapeutic approaches. Our results show that PD-1 expression by CD8 + CD57 + T cells is associated with a reduction of degranulation, cytokine release and cytotoxicity towards EBV-infected targets. This is confirmed by the inverse correlation between functional cytotoxic capacity and PD-1 expression. We also confirm that blockade of PD-1 restores CD8 + CD57 + T effector function, specifically allowing more efficient degranulation, cytokine release and cytotoxicity. Detection of a higher frequency of PD-1 expressing CD8 + CD57 + cells in the blood of patients with RR-MS during clinical remission, and concomitantly suppressed degranulation, suggests a regulatory role of the molecule on cytotoxic function. Notably, CD8 + CD57 + T cells were detected in the inflamed meninges and perivascular infiltrates of postmortem brains of patients with rapidly progressive MS. Although the tissues were from SP-MS and not RR-MS cases, since the latter were not available, selection of cases with high levels of meningeal and perivenular inflammatory infiltrates enabled us to examine inflammatory active pathological processes in post-mortem brain tissue that is expected to share some similarities with RR-MS. Previous studies have shown an association between the extent of meningeal infiltration (as well as increased cortical pathology) and a more rapid disease progression. 49 On the back of this, our finding of a substantial proportion of CD57
+ cells expressing PD-1 in the meningeal infiltrates of post-mortem MS cases suggests the involvement of these cells and molecule in the inflammatory immune response. It is plausible to suggest that the inability of CD8 + CD57 + T cells to clear EBV infection in the CNS enables the persistence of chronic inflammation that underlies the observed more rapid progression of MS. However, we cannot rule out that the CD8 + CD57 + T cells' involvement in the disease process, documented by their detection in MS brain tissue, could be secondary to other inflammatory events occurring in the MS process and that the cells may play a disease-countering role, potentially through immune regulatory mechanisms, as we suggested in one previous report.
50
CD8
+ CD57 + T cells are defined as senescent because of short telomeres, low telomerase activity and low cell cycle-associated genes compared with their CD57 negative was found in the meningeal infiltrates between % of CD3 + CD57 + cells and age at disease progression (k) (r = 0Á4648, P = 0Á0299) and age at death (j) (r = 0Á7185; P = 0Á0020). 52 In addition, CD8 + CD57 + T cells express CX3CR1, the receptor for fractalkine that has been detected in the CSF of patients with early MS and in inflamed MS brain lesions. 53, 54 Interestingly, in our study we show that CD8 + CD57 + T cells express high levels of PD-1 with an exhaustion-like phenotype in patients with MS in the stable phase of the disease, displaying a weak response upon TCR activation with low release of cytokines and granzyme B. Additionally, CD8 + CD57 + T cells from patients with MS in the active phase of the disease display a low expression of PD-1, and high release of IFN-c and granzyme B, consistent with a profile of terminally differentiated effector/cytotoxic virus-specific CD8 + T cells. Our results suggest that the inability of cytotoxic T cells to control EBV replication during inactive MS could set the stage for viral reactivation in the CNS and for disease progression.
The fact that anti-EBV immunity contributes to MS grey matter pathology is strongly supported by an increasing number of studies that correlate cellular and humoral responses to EBV and cortical atrophy or disease activity. CD8 + T-cell responses to EBV lytic and latent antigens increase in active and inactive MS, respectively, displaying a dysfunctional control of the virus. One longitudinal study described an increase of EBV lytic specific CD8 + T cells, associated with the virus reactivation, during the remission of the disease that anticipates the activity (relapse) of the disease in the central nervous system.
11 Also, a cross-sectional study detected EBV RNA and DNA using quantitative PCR in the peripheral blood of patients with MS and healthy donors. 55 It was observed that EBV DNA increases before and during clinical relapse in paired samples suggestive of reactivation of EBV preceding the activity (relapse) of disease in the CNS. In a longitudinal study of patients with RR-MS without treatment, the expansion of CD8 + T cells specific for EBV lytic antigens has been shown to correlate with the occurrence of relapses and disease activity. 56 Impaired CD8 T-cell responses to EBV in MS, assessed by the frequency of PBMC producing IFN-c in response to autologous B-LCL, were also described. 56 Regarding the humoral response to EBV in MS, a significant association between cortical atrophy and anti-EBV viral capsid antigen and EBNA-1 antibody status was found in RR-MS patients. 57 In addition, in a previous study on 193 patients with clinically isolated syndrome the highest quartile antibody status of anti-EBV viral capsid antigen was associated with a greater decrease in thalamus volume and with a trend for a decrease in cortical volume. 58 Moreover, a study on serum of pwMS has shown that EBNA-1 IgG positively correlates with gadolinium-enhancing magnetic resonance imaging lesions, lesion size and expanded Disability Status Scale in patients with MS 59 and in patients with a clinically isolated syndrome with a definitive diagnosis of MS. 60 All this evidence supports a less efficient immune control of EBV infection in patients with MS. An impaired immune response to the virus is evident when the infection becomes chronic. 27 In this case, the virus persists and effector CD8 + T cells become unresponsive and anergic. In contrast to chronic infection, in acute viral infection, the immune system is highly functional and enables clearance of the virus through cytotoxicity against infected cells and secretion of antiviral factors (e.g. interferon). 61 Although those studies support the hypothesis that altered immune reactivity to EBV may favour the reactivation of the virus in intrathecal B cells, which could represent one mechanism causing brain pathology in MS, several studies using similar technologies were unable to detect EBV in the brain tissue and CSF. 14, 15, 48, 62 The discrepant results have been the matter of discussion and it has been suggested that methodological differences, including in the preparation and preservation of the brain tissue, may have affected the sensitivity and specificity of EBV detection. 63 In our study, we have observed a so-called exhausted phenotype of CD8 + CD57 + T cells in inactive disease that leads to an inability of these cells to control EBV replication and consequently favours a reactivation of virus. PD-1 has been described as a marker of activation and differentiation, increasing in early activated EBV-specific cells and decreasing in terminally differentiated effector cells. 64 Low expression of PD-1 on EBV-specific effector cytotoxic CD8 + cells enables the mounting of a response to pathogens and clearance of the infection. In patients with MS during remission, the high expression of PD-1 in CD8 + CD57 + T cells suggests a dysfunctional, reduced cytotoxic response. It is plausible to speculate that PD-1-related suppression of cytotoxicity allows MS-associated viruses such as EBV to persist in the CNS and favours persistent inflammation with tissue damage and consequent relapses. Newly activated CD8 + CD57 + T cells might be induced to clear virus-infected targets in active MS but the repeated antigenic stimulation and inflammatory cytokines contribute to up-regulation of PD-1 with a decrease of effector function. 65 Also, resistance to apoptosis induced by activation in CD8 + CD57 + T cells in patients with MS could correlate with dysfunctional expression of inhibitory receptor PD-1 66 on these cells and could play a role in dictating the occurrence of inflammatory exacerbations in MS (Fig. 9) . One limitation of our study is that we did not examine the potential influence of PD-1 level on the cytotoxicity against other common viruses such as, for example cytomegalovirus and influenza virus. To study EBV responses in the most physiologically relevant way, we generated autologous EBV-LCL to be used as target in the functional assays, focused on the modulation of cytotoxic function by PD-1. As EBV is unique in its ability to induce stable lymphoblastoid cell lines, such an approach could not be used for cytomegalovirus 67, 68 or any non-lymphotropic viruses such as influenza virus. In the absence of a comparison we cannot rule out that the dysfunction of cytotoxic activity against EBV demonstrated by our results in patients with MS might also be observed against other viruses.
Taken together, our data demonstrate that CD8 + CD57 + T cells are polyfunctional effectors that mount cytotoxic and inflammatory responses against EBV-infected cells and infiltrate MS lesion tissue in substantial numbers correlating with disease severity. Their effector functions are down-regulated by PD1, which is over-expressed in stable MS. Our results provide a basis for further studies to evaluate the implication and consider the therapeutic modulation of PD-1 expression in MS. 
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